+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

C

Actively Recruiting

This research aims to evaluate antibiotic treatments for acute pyelonephritis AP in children aged 1 month to 3 years. It compares a shorter intravenous IV antibiotic course of 3 days alone to a longer treatment consisting of 3 days IV followed by 7 days of oral antibiotics. The goal is to see if the shorter IV treatment is as effective in curing AP and preventing recurrence and renal scarring, while reducing the risk of antibiotic resistance and preserving gut microbiota diversity. Participants are randomly assigned to one of two groups. The experimental group receives only 3 days of IV antibiotics with ceftriaxone andor amikacin, after which treatment is stopped. The control group receives the usual care of 3 days IV antibiotics followed by 7 days of oral antibiotics, either cotrimoxazole or cefixime. The study includes collection of fecal or rectal swabs and blood tests to assess microbiota and resistance. Treatment effectiveness and safety are compared between groups. During the study, children are monitored for fever, symptoms, and urine cultures to confirm infection clearance. Researchers measure recurrence of febrile urinary tract infections within 28 days after treatment ends and follow clinical cure at 10 or 17 days depending on the group. Additional assessments include monitoring recurrence at 90 days, antimicrobial resistance in gut bacteria, and intestinal microbiota diversity over about a month. Participation lasts through treatment and follow-up visits up to several weeks.

Age: 1Month - 3YearsAll GendersPhase 4
15 locations
S

Actively Recruiting

Researchers are studying patients with completely removed non-small cell lung cancer NSCLC who have common mutations in the EGFR gene, specifically Del19 or L858R. The study aims to use broad-panel centralized next-generation sequencing NGS testing at the start to better understand molecular factors that predict outcomes and to investigate mechanisms of resistance to the drug osimertinib after treatment. This research focuses on patients with stage pIB to IIIA NSCLC who have undergone thorough preoperative assessments and quality surgical excision reviews. Participants will have plasma circulating tumor DNA ctDNA tested at various stages before surgery optional, 4 to 8 weeks after surgery, before starting adjuvant chemotherapy or osimertinib if given, every 6 months during follow-up, and at relapse if it occurs. Formalin-fixed paraffin-embedded FFPE tissue blocks from surgery and relapse optional will also be collected for molecular analyses. Treatment with osimertinib as adjuvant therapy is planned for up to 3 years, with chemotherapy given beforehand if needed. During the study, patients will be regularly followed every 3 to 6 months with standard care visits and molecular testing. Researchers will monitor the feasibility of the testing approach over 18 months and track the incidence and severity of any side effects related to osimertinib for about 3 years. This ongoing monitoring aims to better understand relapse mechanisms and improve treatment options in metastatic relapse. The total participation duration aligns with the follow-up and safety monitoring periods outlined.

Age: 18Years +All GendersPhase Not Applicable
36 locations
P

Actively Recruiting

Researchers are investigating whether adding cemiplimab, an immunotherapy drug, to neoadjuvant chemotherapy and sequential hypofractionated radiotherapy can improve survival outcomes for unfit or elderly patients with unresectable stage III non-small cell lung cancer NSCLC. The study compares the benefits of neoadjuvant chemotherapy alone versus chemotherapy combined with cemiplimab, followed by radiotherapy and maintenance immunotherapy. This phase II trial aims to assess both the effectiveness and tolerance of these treatments. Participants are randomly assigned to one of two groups one receiving neoadjuvant chemotherapy with carboplatin and paclitaxel alone, and the other receiving the same chemotherapy combined with cemiplimab. Both groups then undergo curative hypofractionated radiotherapy. Following radiotherapy, all participants receive maintenance immunotherapy with cemiplimab every three weeks for 12 months. The neoadjuvant chemotherapy cycles last for three cycles of four weeks each, and radiotherapy consists of 55 Gy over 20 fractions. During the trial, participants will be monitored through scheduled visits and laboratory tests to evaluate disease progression, response rates, survival, and treatment-related toxicity. Quality of life will be assessed using specific questionnaires for lung cancer. The primary outcome is progression-free survival over about 18 months, with secondary outcomes including overall survival and toxicity rates. Participants adherence and safety will be closely tracked throughout the study, which extends up to early 2032.

Age: 18Years +All GendersPhase 2
25 locations
E

Actively Recruiting

Researchers are investigating the role of rifampicin in treating prosthetic joint infections caused by Cutibacterium acnes, which is involved in nearly 40% of shoulder prosthetic joint infections and is a leading cause of late-onset infections after hip and knee prosthesis. The study focuses on the challenges posed by biofilm-associated bacteria in these infections, which have slower growth and may be less responsive to antibiotics. Rifampicin is known for its activity against biofilm-related staphylococcal infections and is being evaluated for its effect on C. acnes infections. Participants receive either amoxicillin or moxifloxacin alone or combined with rifampicin for 12 weeks as antibiotic treatment during surgical revision of infected knee, hip, or shoulder prostheses. The study uses a randomized, parallel design comparing the antibiotic backbone alone versus the combination with rifampicin. Treatment choice between amoxicillin and moxifloxacin is at the investigators discretion. Rifampicin use is being assessed for its impact on treatment outcomes. Throughout the study, participants are monitored for treatment failure and adverse events related to rifampicin up to 24 months after completing antibiotics. The main outcome is the rate of infection management failure 24 months post-treatment. Researchers also track probable failures and failures at 12 months. Safety assessments focus on adverse events during rifampicin therapy. The total study duration includes treatment and long-term follow-up to evaluate both effectiveness and safety.

Age: 18Years +All GendersPhase 3
13 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of EIK1001 combined with Pembrolizumab compared to a placebo plus Pembrolizumab as the first treatment for patients with advanced melanoma. This is a multicenter, randomized, double-blind phase 23 trial that includes dose optimization and expansion parts to assess these therapies. The trial is sponsored by Eikon Therapeutics and targets patients eligible for standard Pembrolizumab therapy. Participants are randomly assigned to one of three groups one receiving a placebo with Pembrolizumab, another receiving a selected dose of EIK1001 plus Pembrolizumab, and a third receiving a different dose of EIK1001 plus Pembrolizumab. EIK1001 is a drug that activates specific immune receptors, and Pembrolizumab is an immune checkpoint inhibitor. The study includes dose optimization in the early phase and expands to larger groups for further evaluation. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, blood tests to monitor organ function, and evaluations of any side effects. Researchers will measure outcomes such as progression-free survival, overall survival, and objective tumor response over a period of up to five years. Safety and adverse events will be closely monitored, particularly during the dose optimization phase. Participants may be followed for up to five years to track long-term effects and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
127 locations
C

Actively Recruiting

Researchers are evaluating two types of endovascular treatments for abdominal aortic aneurysms with short aortic necks measuring between 4 to 15 millimeters. The study compares the safety and performance of Endovascular Aneurysm Repair with EndoAnchor system ESAR using Endurant plus Heli-FX EndoAnchor devices against Fenestrated Endovascular Aneurysm Repair FEVAR using customizable grafts from Cook and Terumo. This randomized trial is sponsored by the Foundation for Cardiovascular Research and Education and focuses on patients who are not candidates for standard EVAR due to challenging anatomy. Participants are randomly assigned to receive either the ESAR treatment, which combines the Endurant II or Endurant IIs endograft with the Heli-FX EndoAnchor system, or the FEVAR treatment, which uses fenestrated grafts such as the Cook Zenith Fenestrated Graft or Terumo Fenestrated Anaconda Graft. Both treatments involve implanting devices to repair the aneurysm by reinforcing the weakened aortic wall and ensuring better sealing in difficult anatomy cases. Treatments are performed as procedures guided by imaging, and patients are monitored over time to assess the outcomes. During the study, participants undergo evaluations including imaging and clinical assessments to measure technical success within 12 months after the procedure and monitor safety by tracking major adverse events within 30 days. Additional follow-ups occur at 1, 12, 24, and 36 months to assess factors such as artery patency, endoleaks, secondary interventions, aneurysm rupture, device migration, and sac size changes. The study also reviews procedure details like contrast volume and fluoroscopy time. Participants are followed for safety and effectiveness for up to three years after treatment.

Age: 18Years +All GendersPhase Not Applicable
33 locations
E

Actively Recruiting

This research aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of new RASON inhibitors in patients with advanced RAS-mutated non-small cell lung cancer NSCLC and other solid tumors. The study focuses on patients with specific KRAS or RAS mutations and uses an open-label platform design including multiple subprotocols to test different drug combinations and monotherapies. Participants are assigned to one of four subprotocols testing various combinations of oral RASON inhibitorsRMC-6291, RMC-6236, and RMC-9805with or without pembrolizumab and chemotherapy. Subprotocols A, B, and C have two parts dose exploration and dose expansion, while Subprotocol D consists of one part. Treatments include oral tablets and intravenous infusions given in specific schedules, such as twice daily BID or once daily QD dosing for oral drugs and every three weeks Q3W for infusions. Throughout the study, participants undergo regular monitoring for adverse events, dose limiting toxicities, and drug concentration levels up to 21 weeks, with antitumor responses and duration of response followed for up to five years. Safety and effectiveness assessments, including laboratory tests and clinical evaluations, are conducted during treatment and long-term follow-up to understand the drugs effects and tolerability in this patient population.

Age: 18Years +All GendersPhase 1Phase 2
98 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness of tarlatamab compared to standard chemotherapy treatments in patients with advanced, poorly differentiated neuroendocrine carcinomas NECs of the lung or gastroenteropancreatic system who have already received prior treatment. This phase 3 trial aims to explore how well tarlatamab works in this patient group, following evidence of its efficacy in small-cell lung cancer. The study is sponsored by the Intergroupe Francophone de Cancerologie Thoracique and focuses on patients with specific tumor characteristics, including DLL3 expression and tumor progression after platinum-based therapy. Participants will be randomly assigned to one of two groups one group will receive tarlatamab at a dose of 10 mg every two weeks, and the other will receive standard chemotherapy chosen by the investigator. Standard chemotherapy options may include immune checkpoint inhibitors, docetaxel, topotecan for lung tumors, or FOLFOX, FOLFIRI, or alkylating-based chemotherapy for digestive tumors. Treatments will be administered according to the schedule determined by the study protocol. During the study, participants will be monitored through various assessments including tumor response evaluations, safety and tolerability checks, and quality of life questionnaires using the EORTC QLQ-C30. The primary outcome is overall survival measured over about four years. Secondary outcomes include objective response rate, duration of response, disease control rate, and progression-free survival. Patients will be followed closely to assess treatment effects and side effects throughout the trial period, which begins after screening and informed consent.

Age: 18Years +All GendersPhase 3
40 locations